Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Neratinib (Primary) ; Everolimus; Palbociclib; Trametinib
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jul 2017 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.
- 10 Jul 2017 Planned primary completion date changed from 1 Jun 2022 to 1 Sep 2022.
- 10 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.